IR News 2025

Kyoto, Japan, January 30, 2025 - Nippon Shinyaku Co., Ltd. (“Nippon Shinyaku”; Headquarters: Kyoto, Japan; President: Toru Nakai) announced that its lawsuit with Sarepta Therapeutics, Inc. ("Sarepta") in Japan ("Lawsuit") has been terminated as of today, January 30, 2025, as a result of Sarepta waiving its claim.

 

On June 5, 2023, Sarepta filed a lawsuit with the Tokyo District Court seeking damages for alleged infringement of Sarepta's patent (Patent No. 6406782) due to Nippon Shinyaku's production, sale, export, etc. of VIRTEPSO, a drug for Duchenne muscular dystrophy (DMD). In response, Nippon Shinyaku argued that Sarepta’s patent was invalid and that there had been no such patent infringement. Sarepta stated that it was waiving its claim at today's (January 30, 2025) court hearing, where the court had planned to render a final judgement, and thus, the Lawsuit has been terminated.

A "waiver of claim" is a way for a plaintiff to terminate litigation by admitting that his or her claim is baseless. When the waiver is entered into the court record, it has the same effect as a final and binding judgment. Sarepta's waiver of claim confirms that Nippon Shinyaku has not infringed on Sarepta's patent. In other words, the result was effectively the same as if Nippon Shinyaku had won the case.

Nippon Shinyaku will continue to contribute to DMD patients, their families, and healthcare professionals.

Corporate Communications Dept., Nippon Shinyaku Co., Ltd.